Yuviwel (Navepegritide)

Navepegritide is a medicine used to help children with achondroplasia, a common form of dwarfism, grow taller. It works by copying a natural signal that helps bones in the growth plates get longer. It's given as a shot under the skin once a week.

Brand names:Yuviwel
Medication

What people taking Yuviwel (Navepegritide) report

Every report comes from a Lived member, sent anonymously.

Have you tried Yuviwel (Navepegritide) for Achondroplasia?

NameHow it went

About Yuviwel (Navepegritide)

What It's For

Navepegritide, sold as Yuviwel, is a once-weekly injection that helps children with achondroplasia grow taller. Achondroplasia is a genetic condition that affects bone growth, causing short stature with arms and legs that are short compared with the trunk. Yuviwel is approved in the US for children age 2 and older whose growth plates are still open. Growth plates are the zones of cartilage near the ends of long bones where growth happens, and they close for good once a person stops growing. The US Food and Drug Administration (FDA) gave Yuviwel accelerated approval in 2026. That means approval rests on a faster measure, how quickly children grew over a year, rather than on proven gains in adult height or fewer complications of achondroplasia. Ongoing studies are meant to confirm the longer-term benefit. A related medicine, vosoritide (Voxzogo), works in a similar way but is injected every day. Yuviwel's main practical difference is the once-a-week schedule.

How It Works

In achondroplasia, a change in a gene called FGFR3 (fibroblast growth factor receptor 3) makes a growth-control signal in the growth plates too active. That signal acts like a brake on the cartilage cells that build new bone, so long bones lengthen more slowly than usual. The body makes its own counterbalancing signal, a hormone called C-type natriuretic peptide (CNP), which encourages those cartilage cells to multiply and mature. Navepegritide is a long-acting form of CNP: the CNP is attached to a carrier that slowly releases it over the week, so one injection keeps CNP active until the next dose. By easing the overactive brake, it lets the growth plates add length faster. It does not change the underlying gene.

Dosage & Administration

Yuviwel comes as a powder in a vial that is mixed with the sterile water supplied in the kit, then injected under the skin once a week, at any time of day. The dose is based on the child's body weight and is adjusted as the child grows; larger doses can require two injections, one after the other in different spots. A parent or caregiver usually gives the injection after training, and the kit's Instructions for Use walk through each step. Injections go into the belly (about 2 inches from the belly button) or the thighs, and a caregiver can also use the buttocks or the back of the upper arm. Changing the spot each week helps avoid skin reactions. If a dose is missed, it can be given up to 2 days after the usual day. After more than 2 days, skip it and give the next dose on the regular day. Doses should be at least 5 days apart. Vials are kept in the refrigerator but can be stored at room temperature for up to 6 months before mixing. A child switching from daily vosoritide starts Yuviwel the day after the last daily dose.

Side Effects

In the main study, the most common side effects were vomiting, reactions where the shot was given (redness, swelling, bruising, itching or pain) and pain in the arms or legs. Each happened somewhat more often than with placebo injections. Some children also noticed extra hair growth, either at injection sites or more generally on the limbs, back or shoulders. Some children develop antibodies to the medicine. In studies these were short-lived and did not appear to affect how well it worked or its safety.

Interactions & Warnings

Medicines in this family can lower blood pressure for a short time; this was seen with the daily version, vosoritide. Contact the care team if a child seems dizzy, unusually tired or nauseated while on Yuviwel. Children with significant heart or circulation problems were not included in the studies, so this deserves discussion before starting. Yuviwel is not recommended for people with moderate or severe kidney disease. No specific drug interactions are known, but interaction studies have not been done, so the care team should know about every other medicine and supplement the child takes. There are no data on use during pregnancy; animal studies did not show harm.

What to Expect

Yuviwel speeds up growth rather than producing a sudden change. In the main study, children on Yuviwel grew about 5.9 cm (a little over 2 inches) in a year, compared with about 4.4 cm on placebo, a difference of about 1.5 cm per year. Children age 5 and older gained more in that year than younger ones. Growth stayed faster through 2 years in children who continued treatment. Whether these yearly gains add up to a meaningfully taller adult height, or reduce other problems linked to achondroplasia, is not yet known. Treatment usually continues for years, with weekly injections becoming part of the family routine. The care team measures growth regularly and updates the dose as weight changes. Treatment stops once the growth plates close and no further growth is possible. Some families weigh the expected gain against the commitment of years of injections, and those decisions are personal.

Questions to Ask Your Doctor

  1. 1.How much extra growth might we realistically expect for my child, and what remains unknown about adult height?
  2. 2.How does once-weekly Yuviwel compare with daily vosoritide for our family?
  3. 3.How will we measure whether it is working, and how often will we have check-ups?
  4. 4.What should we do if my child vomits, feels dizzy or has skin reactions after injections?
  5. 5.Does my child's heart or kidney health affect whether this medicine is a good fit?

Last reviewed • Oct 2026

Educational content, not medical advice.